This article is more than 5 years old. Information may no longer be current.
Pfizer halts global development of bococizumab
Click Here to Manage Email Alerts
Pfizer announced the discontinuation of the global clinical development program for its investigational PCSK9 inhibitor bococizumab, according to a company press release. This will include suspending two ongoing CV outcome studies.
The company cited the “evolving treatment and market landscape for lipid-lowering agents,” in conjunction with trial results, for ending the program.
“As a company, we understand that developing new and important medicines for patients is a critical, but difficult undertaking. Accordingly, we continually evaluate our development programs as data emerge to support prudent decisions that provide value both to the patients we serve and our shareholders,” James Rusnak, MD, PhD, chief development officer of cardiovascular and metabolic diseases at Pfizer, said in the press release. “We are disappointed by this outcome, but remain committed to investing in innovation, concentrating our pipeline on areas where we can bring transformational therapies to address unmet needs, including in patients with [CV] and metabolic diseases.”
Pfizer had previously completed six lipid-lowering studies, all of which met their primary endpoint. The recent trial results showed significant reduction in LDL, according to the release.
Disclosure: Rusnak is an employee of Pfizer.